Navigation Links
Novel Human Tissue Transgenic Cancer Model May Offer Significant,Advance Toward Accurately Modeling Human Cancer

cancer."

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by mid-2007 for AV-951, its oral, second-generation VEGF receptor inhibitor and most advanced clinical program. AV-412, AVEO's EGFR/HER2 inhibitor, is currently in Phase I clinical trials. AV-299, a novel anti-HGF mAb, is currently being manufactured by XOMA under a supply agreement in anticipation of entering the clinic in early 2008. AVEO is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.aveopharma.com.

Contact

AVEO Pharmaceuticals, Inc.
JJ Owen, PhD, 617-299-5889
jjowen@aveopharma.com
or
Pure Communications
Adriana Jenkins, 617-744-1713


'"/>




Page: 1 2 3

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting

Post Your Comments:
(Date:12/3/2009)... Dec. 3 Jazz Pharmaceuti...athryn E. Falberg has been appointed Senior Vice P... brings to Jazz Pharmaceuticals more than 20 years... Jazz Pharmaceutical,s CFO, Ms. Falberg will be re...finance, financial planning, investor relations, a...
(Date:12/3/2009)...ec. 3 ULURU Inc. (NYSE...gical, Inc., one of the major pharmaceutical distr...nc. to be one of its suppliers and has placed its ...n Medical-Surgical delivers a comprehensive offeri... and health care technology-related services to th...
(Date:12/3/2009)...Dec. 3 Stryker Corporati...f Directors has authorized the Company to repurcha...nner, timing and amount of any purchases will be d...ir evaluation of market conditions, stock price an...considerations. Purchases may be made from time t...
Breaking Medicine Technology:ULURU Inc. Obtains Status of Approved Supplier With McKesson. 2Stryker Announces $750 Million Share Repurchase Program and Declares a $0.15 Per Share Quarterly Dividend 2Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th 50387 1Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th 50387 2Connectyx Technologies Holdings Groups CEO Gives Shareholders a Summary of Events for First Half of 2009 and Announces Teleconference Call on July 9th 50387 3Comic Strip Aims to Educate Families About Diabetes 50383 1Publicis Groupe Second Group Most Awarded in Cannes With a Total of 101 Lions 50379 1Publicis Groupe Second Group Most Awarded in Cannes With a Total of 101 Lions 50379 2
(Date:12/3/2009)...., Dec. 3 The Cancer Center at H... patients, Harrington Hospital announced today. ,...y," said Diane Becquart, Director of The Cancer Ce... today by the Massachusetts Department of Public H... facility. ,, The opening of The Cancer Center...
(Date:12/3/2009)...c. 3 /PRNewswire-Asia/ -- Long believed to provide...most important ingredients in global,cuisine, has ...son. , The timing of this ginger demand i... upward price pressures in a way that has speculat...ent demand hysteria over garlic. Garlic, also,beli...
(Date:12/3/2009)..., Md., Dec. 3 We are closer than e...ensures affordable, quality care for all. The Ame...ntact their representatives and voice their suppor...eo from ANA at: http://inr.mediaseed.tv/ANA_37124...system that focuses on wellness and prevention, a ...
(Date:12/3/2009)...ften play out at school and home, study finds , ...ool bullies are also likely to bully their brother...dy that included 195 children between the ages of ...ling no more than four years older or younger than...ullied at school or at home. The findings were pub...
(Date:12/3/2009)...l development of screening test, researcher says,... -- New research points to the possibility of a ge..., People with high blood pressure who had a gene ...ody were found to be twice as likely as those with...the study found. , The finding may lead to a wa...
Breaking Medicine News(10 mins):Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2Health News:Bullies May Intimidate Siblings, Too 2Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2
...nd Blue Shield,of Florida, Inc., (BCBSF) was ranke...alth Plans in Florida," for the second year in a r... National Health Insurance,Plan Study(SM)., (Logo...highest numerical score in the region, 751 of a,po...
...cent of adults,experience back pain at some point ...Carolina this month will launch a free, back care ... is one of the most common medical problems and af...eChoice,HealthPlan Chief Medical Officer Dr. Laura...
... testicular cancer has been a spur to him making t...cisions, and he says, that in retrospect, it was p...o him. But as he approaches the end of his fifth y...r medical checks that might pick up early signs of...
...the world-leading publisher of scientific, technic...today introduced Expert Radiology, a new series of...he among imaging references. , The new Expert Rad...make that information easy to locate and apply. , ...
...ical,Ltd. (Nasdaq: ELOS ), an innovator in the de...d-energy medical aesthetic devices, today announce...ono Bello Contouring Centers,for its LipoLite(TM) ...invasive and non-invasive,body contouring procedur...
...anagement,Services, Inc. (EMSI), the largest provi...and Cybersettle, the world leader in accelerated d...settle users with integrated,medical record retrie...ecord retrieval services will allow parties to res...
Other Medicine News:Health News:Blue Cross and Blue Shield of Florida Awarded Prestigious J.D. Power and Associates Award for Second Year 2Health News:BlueChoice HealthPlan to Launch Back Care Program 2Health News:'Cancer was one of the best things to happen to me... but I worry about the future' 2Health News:New 'Expert Radiology' series fills a gap among available clinical imaging references 2Health News:Syneron Signs Multi-Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite(TM) and VelaShape(TM) 2Health News:Syneron Signs Multi-Year Exclusive Equipment Provider Agreement with Sono Bello Contouring Centers to Offer LipoLite(TM) and VelaShape(TM) 3Health News:EMSI and Cybersettle Partner to Provide Cybersettle Clients With Medical Record Retrieval Services 2
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
...atories is a national reference laboratory and a w...and development. ARUP offers an extensive test men...inical and anatomic pathology. Owned by the Univer...ore than half of the nation's university teaching ...
Medicine Products: